Mathematical model for assessing the level of cross-immunity between strains of influenza virus subtype H3N2

封面

如何引用文章

全文:

详细

Introduction. The WHO regularly updates influenza vaccine recommendations to maximize their match with circulating strains. Nevertheless, the effectiveness of the influenza A vaccine, specifically its H3N2 component, has been low for several seasons.

The aim of the study is to develop a mathematical model of cross-immunity based on the array of published WHO hemagglutination inhibition assay (HAI) data.

Materials and methods. In this study, a mathematical model was proposed, based on finding, using regression analysis, the dependence of HAI titers on substitutions in antigenic sites of sequences. The computer program we developed can process data (GISAID, NCBI, etc.) and create “real-time” databases according to the set tasks.

Results. Based on our research, an additional antigenic site F was identified. The difference in 1.6 times the adjusted R2, on subsets of viruses grown in cell culture and grown in chicken embryos, demonstrates the validity of our decision to divide the original data array by passage histories. We have introduced the concept of a degree of homology between two arbitrary strains, which takes the value of a function depending on the Hamming distance, and it has been shown that the regression results significantly depend on the choice of function. The provided analysis showed that the most significant antigenic sites are A, B, and E. The obtained results on predicted HAI titers showed a good enough result, comparable to similar work by our colleagues.

Conclusion. The proposed method could serve as a useful tool for future forecasts, with further study to confirm its sustainability.

作者简介

Marina Asatryan

National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya

编辑信件的主要联系方式.
Email: masatryan@gamaleya.org
ORCID iD: 0000-0001-6273-8615

PhD (Med.), senior researcher epidemiological cybernetics group of the Epidemiology Department

俄罗斯联邦, 123098, Moscow

Boris Timofeev

National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya

Email: masatryan@gamaleya.org
ORCID iD: 0000-0001-7425-0457

PhD (Phys.-Mat.), senior researcher D.I. Ivanovsky Institute of Virology Division

俄罗斯联邦, 123098, Moscow

Ilya Shmyr

National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya

Email: masatryan@gamaleya.org
ORCID iD: 0000-0002-8514-5174

researcher epidemiological cybernetics group of the Epidemiology Department

俄罗斯联邦, 123098, Moscow

Karlen Khachatryan

National Research University Higher School of Economics

Email: masatryan@gamaleya.org
ORCID iD: 0000-0002-1934-532X

master's student

俄罗斯联邦, 123458, Moscow

Dmitrii Shcherbinin

National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya

Email: masatryan@gamaleya.org
ORCID iD: 0000-0002-8518-1669

PhD (Biol.), researcher, Department of Genetics and Molecular Biology of Bacteria

俄罗斯联邦, 123098, Moscow

Tatiana Timofeeva

National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya

Email: masatryan@gamaleya.org
ORCID iD: 0000-0002-8991-8525

PhD (Biol.), head of laboratory D.I. Ivanovsky Institute of Virology Division

俄罗斯联邦, 123098, Moscow

Elita Gerasimuk

State University “Dubna”

Email: masatryan@gamaleya.org
ORCID iD: 0000-0002-7364-163X

PhD (Med.), Assoc. Prof.

俄罗斯联邦, 141982, Dubna

Vaagn Agasaryan

National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya

Email: masatryan@gamaleya.org
ORCID iD: 0009-0009-3824-7061

researcher epidemiological cybernetics group of the Epidemiology Department

俄罗斯联邦, 123098, Moscow

Ivan Ershov

National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya

Email: masatryan@gamaleya.org
ORCID iD: 0000-0002-3333-5347

researcher epidemiological cybernetics group of the Epidemiology Department

俄罗斯联邦, 123098, Moscow

Tatyana Shashkova

Artificial Intelligence Research Institute

Email: masatryan@gamaleya.org
ORCID iD: 0000-0002-8754-8727

PhD (Biol.), senior researcher Bioinformatics group

俄罗斯联邦, 121170, Moscow

Olga Kardymon

Artificial Intelligence Research Institute

Email: masatryan@gamaleya.org
ORCID iD: 0000-0002-4827-8891

head of Bioinformatics research group

俄罗斯联邦, 121170, Moscow

Nikita Ivanisenko

Artificial Intelligence Research Institute

Email: masatryan@gamaleya.org
ORCID iD: 0000-0002-0333-8117

PhD (Biol.), senior researcher Bioinformatics group

俄罗斯联邦, 121170, Moscow

Tatyana Semenenko

National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya

Email: masatryan@gamaleya.org
ORCID iD: 0000-0002-6686-9011

D. Sci. (Med.), Prof., Full Member of RANS, head Department of Epidemiology

俄罗斯联邦, 123098, Moscow

Boris Naroditsky

National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya

Email: masatryan@gamaleya.org
ORCID iD: 0000-0001-5522-8238

D. Sci. (Biol.), professor, Deputy Director for research D.I. Ivanovsky Institute of Virology Division

俄罗斯联邦, 123098, Moscow

Denis Logunov

National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya

Email: masatryan@gamaleya.org

D. Sci. (Biol.), Full Member of RAS, Deputy Director for research

俄罗斯联邦, 123098, Moscow

Aleksander Gintsburg

National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya

Email: masatryan@gamaleya.org
ORCID iD: 0000-0003-1769-5059

D. Sci. (Biol.), Prof., Full Member of RAS, Director

俄罗斯联邦, 123098, Moscow

参考

  1. Russell C.A., Jones T.C., Barr I.G., Cox N.J., Garten R.J., Gregory V., et al. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine. 2008; 26(Suppl. 4): 31–4. https://doi.org/10.1016/j.vaccine.2008.07.078
  2. Belongia E.A., Simpson M.D., King J.P., Sundaram M.E., Kelley N.S., Osterholm M.T., et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect. Dis. 2016; 16(8): 942–51. https://doi.org/10.1016/S1473-3099(16)00129-8
  3. Jackson M.L., Chung J.R., Jackson L.A., Phillips C.H., Benoit J., Monto A.S., et al. Influenza vaccine effectiveness in the United States during the 2015-2016 season. N. Engl. J. Med. 2017; 377(6): 534–43. https://doi.org/10.1056/NEJMoa1700153
  4. Rolfes M.A., Flannery B., Chung J.R., O’Halloran A., Garg S., Belongia E.A., et al. Effects of influenza vaccination in the United States during the 2017-2018 influenza season. Clin. Infect. Dis. 2019; 69(11): 1845–53. https://doi.org/10.1093/cid/ciz075
  5. Doyle J.D., Chung J.R., Kim S.S., Gaglani M., Raiyani C., Zimmerman R.K., et al. Interim estimates of 2018-2019 seasonal influenza vaccine effectiveness – United States. MMWR. Morb. Mortal. Wkly Rep. 2019; 68(6): 135–9. https://doi.org/10.15585/mmwr.mm6806a2
  6. Zost S.J., Parkhouse K., Gumina M.E., Kim K., Diaz P.S., Wilson P.C., et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc. Natl Acad. Sci. USA. 2017; 114(47): 12578–83. https://doi.org/10.1073/pnas.1712377114
  7. Gouma S., Weirick M., Hensley S.E. Antigenic assessment of the H3N2 component of the 2019-2020 northern hemisphere influenza vaccine. Nat. Commun. 2020; 11(1): 2445. https://doi.org/10.1038/s41467-020-16183-y
  8. Cobey S., Gouma S., Parkhouse K., Chambers B.S., Ertl H.C., Schmader K.E., et al. Poor immunogenicity, not vaccine strain egg adaptation, may explain the low H3N2 influenza vaccine effectiveness in 2012-2013. Clin. Infect. Dis. 2018; 67(3): 327–33. https://doi.org/10.1093/cid/ciy097
  9. Klingen T.R., Reimering S., Guzmán C.A., McHardy A.C. In silico vaccine strain prediction for human influenza viruses. Trends Microbiol. 2018; 26(2): 119–31. https://doi.org/10.1016/j.tim.2017.09.001
  10. Morris D.H., Gostic K.M., Pompei S., Bedford T., Łuksza M., Neher R.A., et al. Predictive modeling of influenza shows the promise of applied evolutionary biology. Trends Microbiol. 2018; 26(2): 102–18. https://doi.org/10.1016/j.tim.2017.09.004
  11. Timofeeva T.A., Asatryan M.N., Al’tshteyn A.D., Naroditskiy B.S., Gintsburg A.L., Kaverin N.V. Predicting the evolutionary variability of the influenza A virus. Acta Naturae. 2017; 9(3): 48–54. https://doi.org/10.32607/20758251-2017-9-3-48-54 https://elibrary.ru/zqitjr
  12. Boev B.V. Modeling of the epidemic of influenza A(H1N1) in Russia season 2009-2010. Epidemiologiya i vaktsinoprofilaktika. 2010; (1): 52–8. https://elibrary.ru/laedxn (in Russian)
  13. Huddleston J., Barnes J.R., Rowe T., Kondor R., Wentworth D.E., Whittaker L., et al. Integrating genotypes and phenotypes improves long-term forecasts of seasonal influenza A/H3N2 evolution. eLife. 2020; 9: e60067. https://doi.org/10.7554/eLife.60067
  14. CDC. Center for Disease Control and Prevention. Influenza (Flu). Available at: https://www.cdc.gov/flu/
  15. Bedford T., Suchard M.A., Lemey P., Dudas G., Gregory V., Hay A.J., et al. Integrating influenza antigenic dynamics with molecular evolution. eLife. 2014; 3: e01914. https://doi.org/10.7554/eLife.01914
  16. Anderson C.S., McCall P.R., Stern H.A., Yang H., Topham D.J. Antigenic cartography of H1N1 influenza viruses using sequence-based antigenic distance calculation. BMC Bioinformatics. 2018; 19(1): 51. https://doi.org/10.1186/s12859-018-2042-4
  17. Lee M.S., Chen J.S. Predicting antigenic variants of influenza A/H3N2 viruses. Emerg. Infect. Dis. 2004; 10(8): 1385–90. https://doi.org/10.3201/eid1008.040107
  18. Lees W.D., Moss D.S., Shepherd A.J. A computational analysis of the antigenic properties of haemagglutinin in influenza a H3N2. Bioinformatics. 2010; 26(11): 1403–8. https://doi.org/10.1093/bioinformatics/btq160
  19. Burnet F.M., Lush D. The action of certain surface active agents on viruses. Aust. J. Exp. Biol. Med. Sci. 1940; 18: 141–50.
  20. Archetti I., Horsfall F.L. Persistent antigenic variation of influenza A viruses after incomplete neutralization in ovo with heterologous immune serum. J. Exp. Med. 1950; 92(5): 441–62. https://doi.org/10.1084/jem.92.5.441
  21. Lapedes A., Farber R. The geometry of shape space: application to influenza. J. Theor. Biol. 2001; 212(1): 57–69. https://doi.org/10.1006/jtbi.2001.2347
  22. Smith D.J., Lapedes A.S., de Jong J.C., Bestebroer T.M., Rimmelzwaan G.F., Osterhaus A.D., et al. Mapping the antigenic and genetic evolution of influenza virus. Science. 2004; 305(5682): 371–6. https://doi.org/10.1126/science.1097211
  23. Wiley D.C., Skehel J.J. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem. 1987; 56: 365–94. https://doi.org/10.1146/annurev.bi.56.070187.002053
  24. Wiley D.C., Wilson I.A., Skehel J.J. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature. 1981; 289(5796): 373–8. https://doi.org/10.1038/289373a0
  25. Wilson I.A., Cox N.J. Structural basis of immune recognition of influenza virus hemagglutinin. Annu. Rev. Immunol. 1990; 8: 737–71. https://doi.org/10.1146/annurev.iy.08.040190.003513
  26. Liao Y.C., Lee M.S., Ko C.Y., Hsiung C.A. Bioinformatics models for predicting antigenic variants of influenza A/H3N2 virus. Bioinformatics. 2008; 24(4): 505–12. https://doi.org/10.1093/bioinformatics/btm638
  27. Asatryan M.N., Agasaryan V.G, Shcherbinin D.N., Timofeev B.I., Ershov I.F., Shmyr I.S., et al. Influenza IDE. Registration certificate № 2020617965; 2020. (in Russian)
  28. Lawson C.L., Hanson R.J. Solving Least Squares Problems. New Jersey: Englewood Cliffs; 1974.
  29. Khalafyan A.A. Mathematical Statistics with Elements of Probability [Matematicheskaya statistika s elementami teorii veroyatnosti]. Moscow: Binom; 2010. (in Russian)
  30. Stephenson I., Gaines Das R., Wood J.M., Katz J.M. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine. 2007; 25(20): 4056–63. https://doi.org/10.1016/j.vaccine.2007.02.039
  31. Wood J.M., Major D., Heath A., Newman R.W., Höschler K., Stephenson I., et al. Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard. Vaccine. 2012; 30(2): 210–7. https://doi.org/10.1016/j.vaccine.2011.11.019
  32. Zacour М., Ward В.J., Brewer A., Tang P., Boivin G., Li Y. Standardization of hemagglutination inhibition assay for influenza serology allows for high reproducibility between laboratories. Clin. Vaccine Immunol. 2016; 23(3): 236–42. https://doi.org/10.1128/CVI.00613-15
  33. The Francis Crick Institute. Worldwide Influenza Centre lab. Annual and interim reports. Available at: https://www.crick.ac.uk/research/platforms-and-facilities/worldwide-influenza-centre/annual-and-interim-reports
  34. DuPai C.D., McWhite C.D., Smith C.B., Garten R., Maurer-Stroh S., Wilke C.O. Influenza passaging annotations: what they tell us and why we should listen. Virus Evol. 2019; 5(1): vez016. https://doi.org/10.1093/ve/vez016
  35. Wu N.C., Zost S.J., Thompson A.J., Oyen D., Nycholat C.M., McBride R., et al. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog. 2017; 13(10): e1006682. https://doi.org/10.1371/journal.ppat.1006682
  36. Park Y.W., Kim Y.H., Jung H.U., Jeong O.S., Hong E.J., Kim H. Comparison of antigenic mutation during egg and cell passage cultivation of H3N2 influenza virus. Clin. Exp. Vaccine Res. 2020; 9(1): 56–63. https://doi.org/10.7774/cevr.2020.9.1.56
  37. Popova L., Smith K., West A.H., Wilson P.C., James J.A., Thompson L.F. Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. PLoS One. 2012; 7(7): e41895. https://doi.org/10.1371/journal.pone.0041895
  38. Klein N.P., Fireman B., Goddard K., Zerbo O., Asher J., Zhou J. Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-2018 influenza season. PLoS One. 2020; 15(2): e0229279. https://doi.org/10.1371/journal.pone.0229279
  39. GISAID. Eurosurveillance; 2017. Available at: https://gisaid.org/resources/commentary-on-gisaid/
  40. Smith T.F., Waterman M.S. Identification of common molecular subsequences. J. Mol. Biol. 1981; 147(1): 195–7. https://doi.org/10.1016/0022-2836(81)90087-5
  41. GetArea. Available at: http://curie.utmb.edu/getarea.html
  42. RCSB PDB: Homepage. Available at: https://www.rcsb.org/
  43. Shcherbinin D.N., Alekseeva S.V., Shmarov M.M., Smirnov Yu.A., Naroditskiy B.S., Gintsburg A.L. The analysis of B-cell epitopes of influenza virus hemagglutinin. Acta Naturae. 2016; 8(1): 13–20. https://doi.org/10.32607/20758251-2016-8-1-13-20 https://elibrary.ru/vsnklb
  44. A standardised numbering for all subtypes of Influenza A hemaggluttin (HA) sequences based on the mature HA sequence. Available at: https://antigenic-cartography.org/surveillance/evergreen/HAnumbering/
  45. Smith D.J., Forrest S., Hightower R.R., Perelson A.S. Deriving shape space parameters from immunological data. J. Theor. Biol. 1997; 189(2): 141–50. https://doi.org/10.1006/jtbi.1997.0495
  46. Kilbourne E.D., ed. The Influenza Viruses and Influenza. London: Academic Press Inc.; 1975.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Asatryan M.N., Timofeev B.I., Shmyr I.S., Khachatryan K.R., Shcherbinin D.N., Timofeeva T.A., Gerasimuk E.R., Agasaryan V.G., Ershov I.F., Shashkova T.I., Kardymon O.L., Ivanisenko N.V., Semenenko T.A., Naroditsky B.S., Logunov D.Y., Gintsburg A.L., 2023

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».